C4 Therapeutics, Inc. (CCCC) Reports In-Line Q2 EPS
Tweet
Share
E-mailGet Alerts CCCC Hot Sheet
Join SI Premium – FREE
C4 Therapeutics, Inc. (NASDAQ: CCCC) reported Q2 EPS of ($0.36), in-line with the analyst estimate of ($0.36). Revenue for the quarter came in at $12 million versus the consensus estimate of $4.78 million.
For earnings history and earnings-related data on C4 Therapeutics, Inc. (CCCC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lutnick Says 'we Trust Anthropic' - Axios
- Delivery Hero boards recommend Uber's €41.50-per-share takeover offer
- Sprinklr (CXM) Tops Q2 EPS by 1c, Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
